Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $91.6 million.

  • Xeris Biopharma Holdings' Cash & Current Investments rose 3198.18% to $91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.6 million, marking a year-over-year increase of 3198.18%. This contributed to the annual value of $71.6 million for FY2024, which is 114.56% down from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Cash & Current Investments stood at $91.6 million, which was up 3198.18% from $59.3 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Cash & Current Investments ranged from a high of $132.1 million in Q1 2022 and a low of $58.4 million during Q1 2025
  • Over the past 5 years, Xeris Biopharma Holdings' median Cash & Current Investments value was $87.4 million (recorded in 2024), while the average stood at $87.3 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 14542.84% in 2021, then tumbled by 4059.74% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Cash & Current Investments (Quarter) stood at $102.4 million in 2021, then grew by 19.07% to $122.0 million in 2022, then plummeted by 40.6% to $72.5 million in 2023, then fell by 1.15% to $71.6 million in 2024, then increased by 27.89% to $91.6 million in 2025.
  • Its last three reported values are $91.6 million in Q3 2025, $59.3 million for Q2 2025, and $58.4 million during Q1 2025.